# US 2023/0143524 A1 · A novel strain of lactobacillus reuteri lm1071 separated from breast milk,and composition for relieving premenstrual syndrome comprising the strain or its culture fluid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0143524 A1
- Document ID: US20230143524A1
- Status: Published application
- Kind: A1
- Application number: 17/796,315
- Filed: 2022-01-21
- Published: 2023-05-11
- Earliest claimed: 2021-02-09
- Assignees: Lactomason Co., Ltd.
- Applicants: Lactomason Co., Ltd.
- Inventors: Minn SOHN; Tae Rahk KIM; Woo Jung PARK
- Web page: https://patentgrep.com/patent/US20230143524A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a strain of Lactobacillus reuteri LM1071 (KCCM12650P) and a composition for relieving menstrual pain, comprising the same. A strain of Lactobacillus reuteri LM1071 (KCCM12650P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO, prostaglandin E2 and leukotriene in blood and increasing epoxyeicosatrienoic acid (EET) and the production ratio of prostaglandin E1/prostaglandin E2. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions and the like.

## Claims

### Claim 1

A strain of Lactobacillus reuteri LM1071 (KCCM12650P).

### Claim 2 (depends on 1)

The strain of claim 1, wherein the strain reduces the production amount of NO in blood.

### Claim 3 (depends on 1)

The strain of claim 1, wherein the strain reduces the secretion amount of prostaglandin E2 in blood.

### Claim 4 (depends on 1)

The strain of claim 1, wherein the strain increases the ratio of prostaglandin E1/prostaglandinE2 in blood.

### Claim 5 (depends on 1)

The strain of claim 1, wherein the strain reduces production of leukotriene in blood.

### Claim 6 (depends on 1)

The strain of claim 1, wherein the strain increases production of epoxyeicosatrienoic acid (EET) in blood.

### Claim 7

A food composition for relieving menstrual pain, comprising:
one or more of a strain of Lactobacillus reuteri LM1071 (KCCM12650P), and culture fluid, fragments and extracts of the strain as active ingredients.

### Claim 8

A pharmaceutical composition for preventing or treating premenstrual syndrome, comprising:
one or more of a strain of Lactobacillus reuteri LM1071 (KCCM12650P), and culture fluid, fragments and extracts of the strain as active ingredients.

### Claim 9 (depends on 8)

The pharmaceutical composition for preventing or treating premenstrual syndrome of claim 8,
wherein the premenstrual syndrome includes edema, breast pain, digestive disorders, headache, back pain, lower abdominal pain, abdominal distention, constipation, diarrhea, depression and insomnia.